<DOC>
	<DOCNO>NCT01333124</DOCNO>
	<brief_summary>This phase II study evaluate efficacy preoperative chemoradiotherapy gemcitabine ( 400mg/m2 , weekly ) resectable pancreatic cancer .</brief_summary>
	<brief_title>Preoperative Chemoradiotherapy With Gemcitabine Resectable Pancreatic Carcinoma</brief_title>
	<detailed_description>The primary objective study evaluate complete ( R0 ) resection rate patient resectable pancreatic cancer treat preoperative chemoradiotherapy curative surgery . An experimental arm result complete resection rate least 90 % would merit study . With 90 % power reject null hypothesis true complete resection rate ≤75 % type I error level 5 % , evaluable 53 patient require . Considering 20 % unevaluable patient due immediate distant metastasis treatment7 , 8 , 17 10 % follow loss , total 64 eligible patient enrol .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Patients resectable pancreatic adenocarcinoma Age 18 year old young 70 year old Performance status ( ECOG scale ) : 01 Adequate organ function Hb ≥9.0 g/dl ANC ≥1,500/mm3 PLT ≥100,000/mm3 Liver function : Total Bilirubin ≤3.0 mg/dl AST/ALT/ALP ≤3× upper limit normal Creatinine ≤1.5 ULN Patients sign write informed consent study entry . Tumor type adenocarcinoma Unresectable resection preoperative evaluation Other primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin prior malignancy treat 5 year ago without recurrence ) Prior systemic therapy ( instance , cytotoxic chemotherapy active/passive immunotherapy ) Prior radiotherapy Major surgery within 4 week prior study treatment Serious illness medical condition , follow ; congestive heart failure ( NYHA class III IV ) unstable angina myocardial infarction within past 6 month , significant arrhythmia require medication conduction abnormality 2nd degree AV block uncontrolled hypertension hepatic cirrhosis ( ≥ Child class B ) interstitial pneumonia , pulmonary adenomatosis psychiatric disorder may interfere and/or protocol compliance unstable diabetes mellitus uncontrolled ascites pleural effusion active infection Received investigational drug agent/procedure , i.e . participation another trial within 4 week begin treatment study drug Pregnant lactate woman Women child bear potential use contraceptive method Sexually active fertile men use effective birth control medication study drug 6 month completion study drug partner woman childbearing potential Any patient judge investigator unfit participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Preoperative chemoradiotherapy Gemcitabine</keyword>
</DOC>